Regeneron Pharmaceuticals, Inc. faces challenges with Eylea sales but sees growth from Dupixent and obesity drugs. Click for my updated look at REGN.

Explore Regeneron Pharmaceuticals analyst ratings and price targets (NASDAQ:REGN) on Benzinga. Stay updated on expert opinions and forecasts for REGN stock.

Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $769.35, accompanied by a high estimate of $975.00 and a low estimate of $547.00.

Regeneron has declined 26.5% over this time frame, while the broader S&P 500 Index has soared 20.7%. Moreover, the stock is down 1.7% on a YTD basis, compared to SPX’s 2.2% gain during the same ...

Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

Investing.com - UBS raised its price target on Regeneron Pharmaceuticals (NASDAQ: REGN) to $584.00 from $560.00 while maintaining a Neutral rating on the stock.According to InvestingPro data ...

On Friday, Bernstein SocGen Group revised its price target for Regeneron (NASDAQ:REGN) Pharmaceuticals (NASDAQ: REGN) to $1,000 from the previous $1,070, while retaining an Outperform rating on ...

On Friday, RBC Capital Markets downgraded Regeneron (NASDAQ: REGN) Pharmaceuticals’ shares, moving the rating from Outperform to Sector Perform.The firm also significantly reduced the price ...

Regeneron Pharmaceuticals (NASDAQ:REGN) has observed the following analyst ratings within the last quarter: According to 13 analyst offering 12-month price targets in the last 3 months, Regeneron ...

Debt Management: Regeneron Pharmaceuticals's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.1. The Significance of Analyst Ratings Explained ...